We are devoted to developing novel therapies against infectious diseases caused by agents such as Human Immunodeficiency Virus (HIV). Our platform technology enables the development of first-in-class antibodies unattainable using current methods. Initial focus is the unmet medical need of 5% HIV-infected patients who cannot be treated with current antiretroviral drugs.